Company’s bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI

GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan. 9 at poster session B.

The presentation, in collaboration with Eleison Pharmaceuticals and the Moffitt Cancer Center, is titled, “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” and will subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.

“The glufosfamide case study in pancreatic cancer successfully showcased the utility of our platform to provide drug developers with an end-to-end analytical tool engineered to resolve multimodal biological complexity at scale,” said BullFrog AI Founder and CEO Vin Singh. “Too much time and capital are wasted in drug development traveling down incorrect pathways, ultimately leaving patients without effective treatments. The power of bfLEAP® and bfPREP™ is their ability to give drug developers a clear path forward based on previous data and indicators to focus on key benchmarks, limiting the amount of wasteful spending on less-than-ideal targets.”

The study explored data-driven precision-oncology approaches leveraging BullFrog AI’s bfLEAP® and bfPREP™ platforms to analyze complex clinical datasets, uncover biologically meaningful patient clusters, and identify patient subtypes that may demonstrate enhanced response to glufosfamide, an investigational chemotherapeutic agent for pancreatic cancer. In the post-hoc analysis of TH-CR-302, a randomized phase 3 clinical trial evaluating glufosfamide against the best supportive care (BSC), the analysis discovered key biomarkers that influenced an almost threefold increase in mean survival from the control to treatment arms.

The research group concluded that ensemble approaches like bfLEAP® can successfully identify patient subgroups within existing glufosfamide clinical trial data. Treatment effect heterogeneity was identified among clusters, identifying possible early predictors of outcomes, and highlighting the effectiveness of data-driven clustering approaches to refine patient stratification and guide the development of personalized treatment strategies.

The study was co-authored by Richard Kim, M.D., Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, Nikolas Naleid, M.D., Pharm.D., Hematology/Oncology Fellow at Moffitt Cancer Center, Eleison Pharmaceuticals, and BullFrog AI.

About BullFrog AI

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:
CORE IR
ir@bullfrogai.com

Media:
CORE PR
pr@bullfrogai.com